ImageneBio (NASDAQ:IMA) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of ImageneBio (NASDAQ:IMA) from a strong sell rating to a hold rating in a research report sent to investors on Saturday.

Separately, Wedbush downgraded ImageneBio from a “neutral” rating to an “underperform” rating in a report on Tuesday, November 25th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $26.50.

ImageneBio Price Performance

ImageneBio stock opened at $5.91 on Friday. The stock has a market capitalization of $66.07 million, a P/E ratio of -0.73 and a beta of 0.44. ImageneBio has a 12-month low of $5.70 and a 12-month high of $18.00. The firm’s 50-day moving average is $6.72 and its two-hundred day moving average is $7.54.

ImageneBio (NASDAQ:IMA) last posted its quarterly earnings data on Tuesday, March 10th. The company reported $0.34 earnings per share for the quarter. As a group, analysts forecast that ImageneBio will post -0.91 EPS for the current year.

Insider Activity at ImageneBio

In related news, Director Joseph P. Slattery acquired 16,000 shares of the business’s stock in a transaction dated Wednesday, December 24th. The shares were acquired at an average cost of $5.99 per share, for a total transaction of $95,840.00. Following the acquisition, the director directly owned 16,000 shares in the company, valued at approximately $95,840. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 5.94% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ImageneBio

A number of institutional investors have recently bought and sold shares of IMA. Goldman Sachs Group Inc. increased its position in ImageneBio by 62.4% during the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after purchasing an additional 29,369 shares during the last quarter. Vanguard Group Inc. acquired a new position in shares of ImageneBio in the 3rd quarter valued at $1,902,000. BML Capital Management LLC purchased a new stake in shares of ImageneBio during the 3rd quarter valued at $1,487,000. Aldebaran Capital LLC purchased a new stake in shares of ImageneBio during the 3rd quarter valued at $159,000. Finally, Blue Owl Capital Holdings LP acquired a new stake in shares of ImageneBio during the 3rd quarter worth $4,409,000. 75.00% of the stock is currently owned by hedge funds and other institutional investors.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.